{"id":"https://openalex.org/W2590539586","doi":"https://doi.org/10.1200/jco.2012.30.30_suppl.82","title":"Immunomodulatory effects of bevacizumab in metastatic malignant melanoma.","display_name":"Immunomodulatory effects of bevacizumab in metastatic malignant melanoma.","publication_year":2012,"publication_date":"2012-10-20","ids":{"openalex":"https://openalex.org/W2590539586","doi":"https://doi.org/10.1200/jco.2012.30.30_suppl.82","mag":"2590539586"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2012.30.30_suppl.82","doi":"https://doi.org/10.1200/jco.2012.30.30_suppl.82","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2012.30.30_suppl.82","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5071440718","display_name":"Aaron Scott Mansfield","orcid":"https://orcid.org/0000-0002-9483-6903","observed_orcids":["https://orcid.org/0000-0002-9483-6903"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aaron Scott Mansfield","raw_affiliation_strings":["Mayo Clinic, Rochester, MN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic, Rochester, MN","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054678780","display_name":"Wendy Kay Nevala","orcid":"https://orcid.org/0009-0004-2256-6715","observed_orcids":["https://orcid.org/0009-0004-2256-6715"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wendy Kay Nevala","raw_affiliation_strings":["Mayo Clinic, Rochester, MN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic, Rochester, MN","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5082719040","display_name":"Svetomir N. Markovic","orcid":"https://orcid.org/0000-0002-9238-4325","observed_orcids":["https://orcid.org/0000-0002-9238-4325"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Svetomir Markovic","raw_affiliation_strings":["Mayo Clinic, Rochester, MN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic, Rochester, MN","institution_ids":["https://openalex.org/I1330342723"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I1330342723"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"30","issue":"30_suppl","first_page":"82","last_page":"82"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.6035000085830688,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.6035000085830688,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.328900009393692,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11313","display_name":"Immune cells in cancer","score":0.021900000050663948,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/metastatic-melanoma","display_name":"metastatic melanoma","score":0.9309999942779541},{"id":"https://openalex.org/keywords/immunomodulation","display_name":"immunomodulation","score":0.9869999885559082},{"id":"https://openalex.org/keywords/angiogenesis-inhibition","display_name":"angiogenesis inhibition","score":0.6740000247955322},{"id":"https://openalex.org/keywords/nab-paclitaxel","display_name":"nab-paclitaxel","score":0.8429999947547913},{"id":"https://openalex.org/keywords/carboplatin","display_name":"carboplatin","score":0.9980000257492065},{"id":"https://openalex.org/keywords/interleukin-6","display_name":"interleukin-6","score":0.9269999861717224},{"id":"https://openalex.org/keywords/peripheral-blood-mononuclear-cells","display_name":"peripheral blood mononuclear cells","score":0.8930000066757202},{"id":"https://openalex.org/keywords/cytokines","display_name":"cytokines","score":0.7179999947547913},{"id":"https://openalex.org/keywords/chemokines","display_name":"chemokines","score":0.8119999766349792},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.5249999761581421}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9453390836715698},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.9404642581939697},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.6532645225524902},{"id":"https://openalex.org/C2781451048","wikidata":"https://www.wikidata.org/wiki/Q415588","display_name":"Carboplatin","level":4,"score":0.6434844136238098},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.6287729740142822},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5667441487312317},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5606029629707336},{"id":"https://openalex.org/C2777292972","wikidata":"https://www.wikidata.org/wiki/Q423762","display_name":"Paclitaxel","level":3,"score":0.4846268594264984},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.47161510586738586},{"id":"https://openalex.org/C2778690821","wikidata":"https://www.wikidata.org/wiki/Q212354","display_name":"Cytokine","level":2,"score":0.45529747009277344},{"id":"https://openalex.org/C2780394083","wikidata":"https://www.wikidata.org/wiki/Q539568","display_name":"Angiogenesis","level":2,"score":0.4452906548976898},{"id":"https://openalex.org/C137061746","wikidata":"https://www.wikidata.org/wiki/Q736033","display_name":"Peripheral blood mononuclear cell","level":3,"score":0.4229472875595093},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.350596159696579},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.19635295867919922},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.11803027987480164},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2012.30.30_suppl.82","doi":"https://doi.org/10.1200/jco.2012.30.30_suppl.82","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2012.30.30_suppl.82","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2037898720","https://openalex.org/W2964478944","https://openalex.org/W4249382411","https://openalex.org/W2144437076","https://openalex.org/W2121820529","https://openalex.org/W7097525801","https://openalex.org/W2549099918","https://openalex.org/W1990352059","https://openalex.org/W2037215924","https://openalex.org/W2056976042"],"abstract_inverted_index":{"82":[0],"Background:":[1],"Metastatic":[2],"malignant":[3],"melanoma":[4,240],"is":[5,272],"a":[6,55,75,186,209,245,253,262],"nearly":[7],"uniformly":[8],"fatal":[9],"disease.":[10],"Systemic":[11],"therapy":[12],"has":[13],"notable":[14],"but":[15],"limited":[16],"success.":[17],"Novel":[18],"therapeutic":[19],"strategies":[20],"are":[21],"urgently":[22],"needed.":[23],"To":[24],"that":[25,196,217],"end,":[26],"we\u2019ve":[27],"pursued":[28],"combinatorial":[29],"therapeutics":[30],"using":[31],"conventional":[32],"chemotherapy":[33,65,92,234],"added":[34,63,90],"to":[35,64,91,110,177,202,223,233],"an":[36],"inhibitor":[37],"of":[38,44,49,51,60,87,102,119,130,168,231,238,269,275],"angiogenesis":[39],"(bevacizumab)":[40],"with":[41,68,95,136],"some":[42],"evidence":[43],"clinical":[45,79,140],"benefit.":[46],"Preliminary":[47],"analysis":[48],"one":[50],"our":[52],"trials":[53,141],"suggested":[54],"previously":[56],"unrecognized":[57],"immunomodulatory":[58,85],"effect":[59,86],"bevacizumab":[61,88,137,232,251],"when":[62,89],"in":[66,93,108,117,150,189,193,212,214,256,265],"patients":[67,94,121,132],"metastatic":[69,96,239],"melanoma,":[70],"and":[71,114,126,129,143,154,244,261],"this":[72],"may":[73],"have":[74],"potential":[76],"impact":[77],"on":[78,139],"outcome.":[80],"Herein":[81],"we":[82],"evaluate":[83],"the":[84,181,194,215,236,273],"melanoma.":[97],"Methods:":[98],"We":[99],"measured":[100],"levels":[101,156],"peripheral":[103],"blood":[104],"mononuclear":[105],"cell":[106,152],"phenotypes":[107],"addition":[109,230],"42":[111],"cytokines,":[112],"chemokines":[113],"growth":[115],"factors":[116],"plasma":[118],"55":[120],"who":[122,133,249],"received":[123,134,197,218,250],"albumin-bound":[124],"paclitaxel":[125],"carboplatin":[127],"(AC)":[128],"73":[131],"AC":[135,203,224],"(ACB)":[138],"N057e":[142],"N0775":[144],"respectively.":[145],"The":[146,170,229],"relative":[147],"percent":[148],"change":[149],"PBMC":[151],"counts":[153],"cytokine":[155],"were":[157],"determined":[158],"from":[159],"baseline":[160],"at":[161],"their":[162],"restaging":[163],"evaluation":[164],"after":[165],"two":[166],"cycles":[167],"therapy.":[169],"Mann":[171],"Whitney":[172],"U":[173],"test":[174],"was":[175,185,208],"used":[176],"compare":[178],"responses":[179],"between":[180],"groups.":[182],"Results:":[183],"There":[184,207],"significant":[187,210,254,263],"increase":[188,255],"CD197+type":[190],"1":[191,259],"macrophages":[192,260],"group":[195,216],"ACB":[198,219],"(35.3%,":[199],"-11.8-142.7%)":[200],"compared":[201,222],"(-11.6%,":[204],"-45.9-38.3%;":[205],"p=0.004).":[206],"decrease":[211,264],"IL-6":[213],"(-42.4%,":[220],"-87.7-0.0%)":[221],"(28.4%,":[225],"-37.4-480%;":[226],"p=0.0018).":[227],"Conclusions:":[228],"for":[235],"treatment":[237],"modulates":[241],"cellular":[242],"immunity":[243],"pro-inflammatory":[246],"cytokine.":[247],"Patients":[248],"had":[252],"CD197+":[257],"type":[258],"IL-6.":[266],"Clinical":[267],"significance":[268],"these":[270],"findings":[271],"subject":[274],"ongoing":[276],"work.":[277]},"counts_by_year":[],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2017-03-03T00:00:00"}